16 completed, 6 recruiting, 6 terminated, 4 withdrawn. 10 Phase 2, 8 Phase 4, 7 Phase 1, 6 Phase 3, 4 Not applicable.
Follow Bumetanide: new trials by email Literature Review of Bumetanide trials Research Report on Bumetanide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bumetanide vs. Furosemide in Cirrhosis Bumetanide, Furosemide - Cirrhosis | Phase 3 | Recruiting | Stacy Johnson | 500 | 2026-06-03 | 2026-06-16 |
| VAPorized Administration of Bumetanide for Outpatient Relief in Heart Failure Bumetanide, intranasal 4mg - Heart Failure Congestive | Phase 4 | Withdrawn | Prisma Health-Upstate | 2026-01-21 | 2026-01-29 | |
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models Bumetanide, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 66 | 2025-06-04 | 2026-04-29 |
| EU Sites: Fluid Management of Acute Decompensated Heart Failure With Reprieve Decongestion Management System (FASTR-EU) Reprieve Decongestion Management System, Diuretic (furosemide, bumetanide, torsemide, hydrochlorothiazide, and/or acetazolamide) - Acute Decompensated Heart Failure | Not applicable | Completed | Reprieve Cardiovascular, Inc | 12 | 2024-05-17 | 2025-03-10 |
| A Study of Ultra High Dose Diuretics to Treat Heart Failure Bumetanide, Furosemide - Heart Failure; With Decompensation | Phase 2 | Completed | Mayo Clinic | 20 | 2023-11-27 | 2026-01-14 |
| Bumetanide in Patients With Alzheimer's Disease Bumetanide, Placebo - Alzheimer Disease | Phase 2 | Recruiting | Stanford University | 40 | 2023-04-10 | 2026-01-14 |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Efficacy of Bumetanide to Improve Cognitive Functions in Down Syndrome Bumetanide, Placebo - Down Syndrome | Phase 2 | Unknown | Stefano Vicari | 64 | 2023-01-11 | 2024-06-20 |
| Safety and Pharmacokinetic Study of NPT 2042 Soft-gelatin Capsules Administered Orally to Healthy Adult Subjects NPT 2042 (bumetanide analog) or Matching Placebo - Epilepsy, Alzheimer Disease | Phase 1 | Completed | NeuroPro Therapeutics, Inc. | 50 | 2022-10-20 | 2023-04-04 |
| Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial Low dose combination polydiuretic therapy, Comparator monotherapy empagliflozin - Heart Failure With Preserved Ejection Fraction | Phase 4 | Terminated | The George Institute | 3 | 2022-10-01 | 2024-11-21 |
| Diuretic Treatment in Acute Heart Failure With Volume Overload Guided by Serial Spot Urine Sodium Assessment UNa measurement after intravenous loop diuretic bolus, Intravenous acetazolamide 500 mg OD, Intravenous bumetanide TID - Acute Heart Failure, Diuretics Drug Reactions | Phase 4 | Completed | Vrije Universiteit Brussel | 107 | 2022-06-12 | 2026-09-11 |
| Mechanisms of Diuretic Resistance in Heart Failure, Aim 1 Bumetanide Injection - Heart Failure | Phase 1 | Recruiting | Yale University | 75 | 2022-06-01 | 2026-05-22 |
| Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts Furosemide, Torsemide, Bumetanide - Heart Failure, Congestive | Phase 4 | Recruiting | Heart Center Research, LLC | 80 | 2021-07-08 | 2024-01-29 |
| Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg - HF - Heart Failure, Diabetes Mellitus | Phase 4 | Withdrawn | Northwestern University | 2021-01-08 | 2022-05-10 | |
| Role of Bumetanide in Treatment of Autism Bumetanide, Placebo - Autism | Phase 3 | Recruiting | Sherief Abd-Elsalam | 80 | 2021-01-01 | 2021-02-23 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: - Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension | Recruiting | Duke University | 5000 | 2020-03-05 | 2026-08-21 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Chlortalidone and Bumetanide in Advanced Chronic Kidney Disease: HEBE-CKD Trial Chlorthalidone, Bumetanide - Renal Insufficiency, Chronic | Phase 2 | Completed | Hospital General de México Dr. Eduardo Liceaga | 34 | 2019-06-18 | 2020-11-23 |
| Oral dIuretics in Very Intensive Treatment, an Early Intervention in Outpatients With Heart Failure Bumetanide 1 MG - Heart Failure, Congestive Heart Failure | Phase 4 | Unknown | Centro en Insuficiencia Cardiaca, Mexico | 40 | 2018-10-15 | 2018-10-17 |
| Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52 - Autism Spectrum Disorder (ASD) | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 211 | 2018-10-04 | 2023-06-05 |
Showing 20 of 35. Sign in to see all of them.
Heart Failure (10) · Edema (5) · Autism Spectrum Disorder (4) · Autistic Disorder (3) · Hypertension (3) · Renal Insufficiency, Chronic (3) · Alzheimer Disease (2) · Down Syndrome (2) · Hypoxia-Ischemia, Brain (2) · Adrenal Insufficiency (1) · Arrhythmias, Cardiac (1) · Attention Deficit Disorder with Hyperactivity (1) · Body Weight (1) · Bronchopulmonary Dysplasia (1) · COVID-19 (1)
Institut de Recherches Internationales Servier (2) · Yale University (2) · AstraZeneca (1) · Central Hospital, Nancy, France (1) · Centro en Insuficiencia Cardiaca, Mexico (1) · Duke University (1) · Fei Li (1) · Great Ormond Street Hospital for Children NHS Foundation Trust (1) · Hasselt University (1) · Heart Center Research, LLC (1) · Hospital General de México Dr. Eduardo Liceaga (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · NeuroPro Therapeutics, Inc. (1)
United States (18) · France (5) · United Kingdom (4) · Italy (3) · Netherlands (3) · Poland (3) · Australia (2) · Belgium (2) · Brazil (2) · Canada (2) · China (2) · Hungary (2) · Mexico (2) · Portugal (2) · Spain (2)
Abeer Salamah, Dr (1) · Adam P Bress, PharmD, MS (1) · Chi Hornik (1) · Clare Arnott (1) · Doreen Fialho, MD, PhD (1) · El Mehdi Siaghy (1) · Esraa Shaker, Msc (1) · Fabio Solis-Jimenez, M.D. (1) · Fei Li, doctor (1) · Frederik H Verbrugge, M.D.; Ph.D.; M.Sc. (1) · Frederik H. Verbrugge, M.D. Ph.D. (1) · Hooman Yarmohammadi, MD (1)
PMID 39816573, PMID 23233021, PMID 25765333, PMID 29440005, PMID 29587582, PMID 31074184, PMID 33891615, PMID 35460884, PMID 36127661, PMID 36810101, PMID 36896716, PMID 37794745, PMID 37932787, PMID 38447632, PMID 39048932, PMID 40295876, PMID 40938670
2017 (2), 1IK2CX002368-01A1 (1), R01DK130997 (1), R01HL128973 (1), R01NS066929 (1)